Investors Buy Large Volume of Call Options on Sangamo Therapeutics (NASDAQ:SGMO)

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) was the target of some unusual options trading on Tuesday. Stock traders purchased 4,583 call options on the stock. This is an increase of approximately 61% compared to the typical volume of 2,839 call options.

Sangamo Therapeutics Stock Performance

Shares of Sangamo Therapeutics stock traded up $0.02 during trading hours on Friday, hitting $0.47. The company's stock had a trading volume of 5,907,196 shares, compared to its average volume of 8,729,440. The business has a 50 day moving average price of $0.73 and a two-hundred day moving average price of $1.32. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The company has a market cap of $107.72 million, a PE ratio of -0.63 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last announced its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.03). Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. The business had revenue of $6.44 million during the quarter, compared to analysts' expectations of $7.90 million. As a group, research analysts anticipate that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several large investors have recently made changes to their positions in the business. Point72 Asset Management L.P. purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter worth about $2,316,000. Geode Capital Management LLC lifted its position in shares of Sangamo Therapeutics by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock worth $2,257,000 after buying an additional 73,540 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Sangamo Therapeutics in the fourth quarter worth about $1,744,000. Jacobs Levy Equity Management Inc. lifted its position in shares of Sangamo Therapeutics by 74.8% in the first quarter. Jacobs Levy Equity Management Inc. now owns 1,297,785 shares of the biopharmaceutical company's stock worth $851,000 after buying an additional 555,323 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Sangamo Therapeutics by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company's stock worth $1,162,000 after buying an additional 35,926 shares in the last quarter. 56.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have commented on the company. Royal Bank of Canada restated a "sector perform" rating and issued a $2.00 price target on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Sangamo Therapeutics in a research note on Monday, April 7th. Barclays dropped their price target on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday. Finally, Truist Financial decreased their price objective on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $4.50.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.